#513: Advancing Chronic Disease Development: Insights from FDA, EMA, PMDA, and MHRA
Tuesday, June 16, 2026 10:15 AM to 11:30 AM · 1 hr. 15 min. (America/New_York)
201AB
02: ClinicalTrialOps-Innovation08: RegPolicy-Strategy-GlobalCollaboration
Information
Chronic Disease Town Hall spotlights emerging programs and global initiatives for chronic disease drug development, outlines the current landscape, explores opportunities and challenges, and assesses strategies to boost efficiency and accelerate therapeutic innovation.
CE
ACPECMERN
Session Level
Intermediate
Featured Topics
Global Alignment in PracticeStudent and Early Career PathwayTherapeutic Pathways
Learning Objectives
Discuss the present landscape, opportunities, and challenges of chronic disease drug development; Describe emerging programs and global initiatives designed to facilitate development of chronic disease drugs; Assess various considerations and strategies to enhance the efficiency of chronic disease drug development.
Speakers
Jingyu (Julia) Luan
Executive Regulatory Science DirectorAstraZeneca
Alison Cave
Chief Safety OfficerMedicines and Healthcare Products Regulatory Agency (MHRA)
Jeffrey Siegel
Director, Office of Drug Evaluation Sciences, OND, CDERFDA
Steffen Thirstrup
Chief Medical OfficerEuropean Medicines Agency
Ayaka Kubota
Office of Safty IIPharmaceuticals and Medical Devices Agency (PMDA)RS
Raymond Soccio
Supervisory PhysicianFDAFS
Fred Senatore
Medical Officer, Clinical Team Leader Div of Cardiology & Nephrology, OND, CDERFDARB
Ruth Belin
Vice President, CardioMetabolic Health & Neuroscience Regulatory, AmericasEli Lilly and Company
